Dimerix Partners with Everest Medicines to Expand DMX-200 Commercialization Across Asia

Australian clinical-stage biopharmaceutical company Dimerix Limited has entered into an exclusive licensing agreement with Everest Medicines, based in Shanghai, China, for the commercialization of its lead drug candidate, DMX-200.

Under the agreement, Everest Medicines will receive exclusive rights to commercialize DMX-200 across Greater China, including mainland China, Hong Kong SAR, Macao SAR, and Taiwan, as well as South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines.

Dimerix will retain all commercialization rights for DMX-200 in territories that have not already been exclusively licensed.

DMX-200 Targets a Rare and Serious Kidney Disease

DMX-200 is a small-molecule inhibitor of chemokine receptor 2 (CCR2) currently being evaluated in the pivotal Phase 3 ACTION3 clinical trial for the treatment of Focal Segmental Glomerulosclerosis (FSGS).

FSGS is a rare kidney disease that can lead to progressive kidney damage and, in many cases, kidney failure. Patients with the condition often have limited treatment options, making the development of new therapies a significant area of focus.

The ACTION3 Phase 3 adult study has completed patient enrollment, with 333 participants recruited globally, including patients from territories covered under the Everest Medicines licensing agreement.

Positive Progress Reported from the ACTION3 Trial

Dimerix has continued to report encouraging progress from the ongoing Phase 3 study.

In early 2024, the company announced positive interim results showing that DMX-200 was outperforming placebo in reducing proteinuria, a key indicator of kidney damage in FSGS patients.

The company also reported that no safety concerns have been identified so far. The independent Data Monitoring Committee has reviewed the study eight times, with the latest review completed in June 2026.

In April 2026, an external blinded statistical review confirmed that the ACTION3 trial remains appropriately powered to achieve its primary endpoint. According to the review, if DMX-200 continues to demonstrate the expected reduction in proteinuria, there is more than a 90% probability that the trial will achieve a statistically significant result at completion.

Dimerix Sees Opportunity to Reach More Patients

Dr. Nina Webster, Chief Executive Officer and Managing Director of Dimerix, said the partnership represents an important step in expanding access to DMX-200 across Asia.

According to Webster, Everest Medicines brings strong expertise in rare kidney diseases and has a proven track record of commercializing innovative therapies in Greater China, South Korea, and Southeast Asia.

She noted that the collaboration allows Dimerix to extend the potential reach of DMX-200 into large underserved patient populations while continuing to focus on its global registration program and development activities.

Everest Medicines Expands Its Kidney Disease Portfolio

Everest Medicines views the agreement as a strategic addition to its growing renal disease portfolio.

Yifang Wu, Chairman of the Board at Everest Medicines, said patients with FSGS in China continue to face significant unmet medical needs because targeted treatment options remain limited.

He added that the positive interim Phase 3 data for DMX-200 highlight the therapy’s potential to become an important treatment option for patients living with the disease.

Everest plans to leverage its clinical development and commercialization capabilities to accelerate access to DMX-200 across the licensed regions while also exploring opportunities in other kidney disorders.

Responsibilities Under the Agreement

Under the terms of the partnership, Dimerix will continue to fund and manage the global ACTION3 Phase 3 clinical trial.

Everest Medicines will be responsible for regulatory submissions, regulatory maintenance, and all commercialization-related activities within the licensed territories.

The two companies will also establish a Joint Steering Committee to coordinate development and commercialization activities for DMX-200 in FSGS across the partnership regions.

Deal Includes Upfront Payment and Potential Milestones

As part of the agreement, Dimerix will receive an upfront payment of $10 million, approximately AU$14.1 million, within 45 business days of signing the deal.

The company is also eligible to receive:

• Up to $30 million in development and regulatory milestone payments.
• Up to $300 million in commercial milestone payments.
• Tiered royalties ranging from 10% to 15% on net sales of DMX-200 across Greater China, South Korea, and selected Southeast Asian markets.

The total potential value of the agreement reflects the growing commercial opportunity for DMX-200 as it advances through late-stage development for FSGS and potentially other kidney diseases.

Growing Momentum for DMX-200

The licensing agreement marks another major milestone for Dimerix as the company continues advancing DMX-200 through Phase 3 development.

With full enrollment completed in the ACTION3 study, positive interim efficacy data, ongoing safety reviews, and a new commercialization partner covering key Asian markets, the program continues to build momentum as it moves toward potential regulatory submissions and future commercialization.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!